INT112210

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 6.75
Pain Relevance 4.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc6a1) plasma membrane (Slc6a1)
Anatomy Link Frequency
tail 2
spinal 1
amacrine cells 1
Slc6a1 (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 6 99.84 Very High Very High Very High
Analgesic 2 99.76 Very High Very High Very High
opioid receptor 4 99.52 Very High Very High Very High
depression 12 98.96 Very High Very High Very High
addiction 2 98.90 Very High Very High Very High
Morphine 8 98.70 Very High Very High Very High
opiate 1 98.40 Very High Very High Very High
GABAergic 21 98.28 Very High Very High Very High
Antinociceptive 4 97.64 Very High Very High Very High
Neuropathic pain 4 97.24 Very High Very High Very High
Disease Link Frequency Relevance Heat
Targeted Disruption 29 100.00 Very High Very High Very High
Pain 6 99.84 Very High Very High Very High
Depression 12 98.96 Very High Very High Very High
Morphine Dependence 2 98.90 Very High Very High Very High
Nociception 10 98.80 Very High Very High Very High
Anxiety Disorder 15 98.32 Very High Very High Very High
Frailty 10 97.80 Very High Very High Very High
Neuropathic Pain 4 97.24 Very High Very High Very High
Cytomegalovirus Infection 2 96.36 Very High Very High Very High
Death 1 94.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this paper, we observed the behavioral alterations of GAT1 knockout (GAT1(-/-)) mice using several depression- and anxiety-related models (eg, the forced-swimming test and the tail-suspension test for testing depression-related behaviors; the open-field test, the dark-light exploration test, the emergence test, and the elevated plus maze (EPM) test for anxiety-related behaviors).
Regulation (alterations) of GAT1 in tail associated with targeted disruption, depression and anxiety disorder
1) Confidence 0.62 Published 2007 Journal Neuropsychopharmacology Section Abstract Doc Link 17164814 Disease Relevance 0.83 Pain Relevance 0.46
However, the contributions of the GAT1 in regulating mental status are not fully understood.
Regulation (regulating) of GAT1
2) Confidence 0.45 Published 2007 Journal Neuropsychopharmacology Section Abstract Doc Link 17164814 Disease Relevance 0.69 Pain Relevance 0.33
In this paper, we observed the behavioral alterations of GAT1 knockout (GAT1(-/-)) mice using several depression- and anxiety-related models (eg, the forced-swimming test and the tail-suspension test for testing depression-related behaviors; the open-field test, the dark-light exploration test, the emergence test, and the elevated plus maze (EPM) test for anxiety-related behaviors).
Regulation (alterations) of GAT1 in tail associated with targeted disruption, depression and anxiety disorder
3) Confidence 0.45 Published 2007 Journal Neuropsychopharmacology Section Abstract Doc Link 17164814 Disease Relevance 0.82 Pain Relevance 0.45
To study further the effects of GAT1 on pain, we used two kinds of GAT1-overexpressing transgenic mice (under the control of a CMV promoter or a NSE promoter) to examine the nociceptive responses in these mice.
Regulation (effects) of GAT1 associated with nociception, targeted disruption, pain and cytomegalovirus infection
4) Confidence 0.45 Published 2003 Journal J. Neurosci. Res. Section Abstract Doc Link 12898541 Disease Relevance 1.16 Pain Relevance 0.72
The results indicate that GAT1 is involved in the regulation of pain processes, and point to the possibility of developing analgesic drugs that target GAT1 other than opioid receptors.
Regulation (target) of GAT1 associated with pain, analgesic and opioid receptor
5) Confidence 0.27 Published 2003 Journal J. Neurosci. Res. Section Abstract Doc Link 12898541 Disease Relevance 1.14 Pain Relevance 0.76
These findings suggest that the GABAergic system plays an important role in morphine addiction and point to the possibility of developing drugs that target GAT1 and extend the clinical application of opiates.
Regulation (target) of GAT1 associated with addiction, gabaergic, opiate and morphine
6) Confidence 0.27 Published 2003 Journal J. Neurosci. Res. Section Abstract Doc Link 14598306 Disease Relevance 0.48 Pain Relevance 1.13
Concordantly, reductions in both GAD65 and GAD67 and GAT1 immunoreactivity also support the observation of a loss of GABAergic inhibition and the associated spinal interneurons.
Regulation (immunoreactivity) of GAT1 in spinal associated with gabaergic
7) Confidence 0.15 Published 2010 Journal J. Neurotrauma Section Abstract Doc Link 20059302 Disease Relevance 1.51 Pain Relevance 1.02
GAD67 and GAT-1 immunoreactivities were localized in numerous amacrine and displaced amacrine cells, with somata in the INL and GCL, respectively, and in densely distributed immunoreactive processes and puncta in all laminae of the IPL (Figure 7) [37,51-56].
Regulation (immunoreactivities) of GAT-1 in amacrine cells
8) Confidence 0.07 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2519030 Disease Relevance 0.13 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox